Nuvation Bio [NUVB] vs Vertex [VRTX] Detailed Stock Comparison

Nuvation Bio Inc.

NYSE
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Nuvation Bio Inc. wins in 4 metrics, Vertex Pharmaceuticals Inc. wins in 14 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Nuvation Bio Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 5.81 5.92 Nuvation Bio Inc.
Debt-to-Equity Ratio 21.90 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -35.31 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -6.23 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 85.22% 32.94% Nuvation Bio Inc.
Operating Margin (TTM) -81.30% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -53.18% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -23.46% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-181.78M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 125.47% 1.24% Nuvation Bio Inc.
Price-to-Sales Ratio (TTM) 28.30 9.22 Vertex Pharmaceuticals Inc.
Enterprise Value $1.32B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio 20.94 8.83 Vertex Pharmaceuticals Inc.
Gross Profit Margin (TTM) 96.94% 85.39% Nuvation Bio Inc.
Revenue per Share (TTM) $0 $47 Vertex Pharmaceuticals Inc.
Earnings per Share (Diluted) $-0.60 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.61 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 23.23% 1.78% Vertex Pharmaceuticals Inc.

Nuvation Bio Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

NUVB
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Nuvation Bio Inc.-3.67%-0.42%7.03%8.26%-43.61%-44.99%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Nuvation Bio Inc.125.47%179.53%-60.98%-51.96%-51.96%-51.96%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Nuvation Bio Inc. vs Vertex Pharmaceuticals Inc.

MetricNUVBVRTX
Market Information
Market Cap i$1.75B$109.45B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i2,882,9771,057,061
90 Day Avg. Volume i3,312,7821,272,097
Last Close$4.72$428.34
52 Week Range$1.57 - $9.75$362.50 - $507.92
% from 52W High-51.59%-15.67%
All-Time High$15.23 (May 24, 2021)$519.88 (Nov 04, 2024)
% from All-Time High-69.01%-17.61%
Growth Metrics
Quarterly Revenue Growth6.33%0.10%
Quarterly Earnings Growth6.33%0.31%
Financial Health
Profit Margin (TTM) i0.85%0.33%
Operating Margin (TTM) i-0.81%0.40%
Return on Equity (TTM) i-0.53%0.23%
Debt to Equity (MRQ) i21.9010.91
Cash & Liquidity
Book Value per Share (MRQ)$0.88$73.49
Cash per Share (MRQ)$1.52$26.01
Operating Cash Flow (TTM) i$-173,427,008$3.63B
Levered Free Cash Flow (TTM) i$-115,776,248$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Nuvation Bio Inc. vs Vertex Pharmaceuticals Inc.

MetricNUVB (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-35.3119.95
PEG Ratio i-35.310.88
Price to Sales (TTM) i28.309.22
Price to Book (MRQ) i5.815.92
Market Capitalization
Market Capitalization i$1.75B$109.45B
Enterprise Value i$1.32B$105.96B
Enterprise Value Metrics
Enterprise to Revenue i20.948.83
Enterprise to EBITDA i-6.2321.78
Risk & Other Metrics
Beta i1.610.37
Book Value per Share (MRQ) i$0.88$73.49

Financial Statements Comparison: Nuvation Bio Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricNUVB (2025)VRTX (2025)
Revenue/Sales i62.90M12.00B
Cost of Goods Sold i9.30M1.65B
COGS % of Revenue i14.8%13.8%
Gross Profit i53.60M10.35B
Gross Margin i85.2%86.2%
Research & Development i115.11M4.04B
Operating Income (EBIT) i-213.06M4.55B
Operating Margin i-338.7%37.9%
EBITDA i-188.37M5.25B
EBITDA Margin i-299.5%43.7%
Pre-Tax Income i-204.63M4.64B
Pre-Tax Income % of Revenue i-325.3%38.7%
Income Tax i0690.00M
Income Tax % of Revenue i0.0%5.7%
Net Income (Profit) i-204.63M3.95B
Profit Margin i-325.3%32.9%

Balance Sheet & Liquidity Metrics

MetricNUVB (2025)VRTX (2025)
Cash & Equivalents i164.09M5.08B
Total Current Assets i571.52M11.20B
Total Current Assets % of Revenue i908.6%93.3%
Total Current Liabilities i82.23M3.86B
Total Current Liabilities % of Revenue i130.7%32.2%
Long-Term Debt i49.75M1.95B
Long-Term Debt % of Revenue i79.1%16.3%
Total Shareholders Equity i305.72M18.67B
Retained Earnings i-1.12B13.56B
Retained Earnings % of Revenue i-1,773.2%113.0%
Property, Plant & Equipment i3.92M1.56B

Cash Flow Statement Comparison

MetricNUVB (2025)VRTX (2025)
Operating Cash Flow i-175.98M3.77B
Operating Cash Flow % of Revenue i-279.8%31.4%
Capital Expenditures i-354,000-437.60M
Free Cash Flow i-181.78M3.19B
FCF Margin i-289.0%26.6%
Debt Repayment i-11.90M-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricNUVBVRTX
Shares Short i48.73M4.02M
Short Ratio i9.622.80
Short % of Float i23.23%1.78%
Shares Outstanding i346.50M253.99M
Float Shares i237.04M253.24M
% Held by Insiders i18.67%0.21%
% Held by Institutions i62.24%97.60%
% Held by Public i19.09%2.19%

Dividend Analysis & Yield Comparison: Nuvation Bio Inc. vs Vertex Pharmaceuticals Inc.

MetricNUVBVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A